Analysis of the cytotoxic activity of carboplatin and gemcitabine combination.
OBJECTIVE
To determine if the drug doses and administration schedules of carboplatin and gemcitabine combination affect antitumor effects.


METHODS
The inhibition of cell viability was measured by MTT assay. Median effect analysis was conducted to determine the cytotoxicity activity of carboplatin and gemcitabine combination. Cell cycle changes were analyzed by flow cytometry.


RESULTS
Synergism was observed when the bladder cancer cell line 5637 cells were treated with gemcitabine followed by carboplatin or concurrent carboplatin/gemcitabine. In contrast, moderate antagonism was observed when cells were treated with carboplatin followed by gemcitabine. Cell cycle analysis showed that the combined effect of these two drugs was cell cycle disturbance.


CONCLUSIONS
Different doses and administration schedules affect the antitumor effect of carboplatin/gemcitabine combination that may have clinical significance in the treatment for bladder cancer.
Division of Hematology and Oncology, Department of Internal Medicine, UC Davis Cancer Center, Sacramento, CA 95817, USA.
Sisi
S
Wang
Hongyong
H
Zhang
Liang
L
Cheng
Christopher
C
Evans
Chong-Xian
CX
Pan
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D016190:Carboplatin / Q000008:administration & dosage; D002453:Cell Cycle / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004357:Drug Synergism; D005434:Flow Cytometry; D006801:Humans; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000093542:Gemcitabine
D003841:Deoxycytidine; D016190:Carboplatin; D000093542:Gemcitabine